$3.21-0.04 (-1.23%)
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and ...
BioLine Rx Ltd (BLRX) reports increased revenue and APHEXDA sales, while navigating a net loss and competitive pressures in the glioblastoma treatment landscape.
BioLineRx Ltd. (NASDAQ:BLRX) reported first-quarter 2026 financial results on Wednesday, shortly after announcing that the first patient had been dosed in its Phase 1/2a clinical study evaluating GLIX1 for the treatment of glioblastoma.
Despite a significant revenue drop, BioLine Rx Ltd (BLRX) focuses on innovative treatments and maintains a strong cash position to drive future growth.
BioLine Rx Ltd (BLRX) reports reduced net loss and strategic developments in cancer treatment, bolstered by a strong cash position.
BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows the company’s participation in ASCO 2025, where the management presented full data from the pilot phase of its […]